SCIENTIFIC PROGRAMME
SESSION I
HOW I TREAT
SMOLDERING MYELOMA
(SMM)
SESSION II
HOW I TREAT NEWLY
DIAGNOSED MULTIPLE
MYELOMA
SESSION III
FROM RISK
STRATIFICATION TO
RISK-BASED THERAPY?
DEBATE 1
SHOULD WE USE MRD
TESTING TO DETERMINE
THERAPY IN MULTIPLE
MYELOMA?
DEBATE 2
IS THERE A FUTURE ROLE
OF AUTOLOGOUS STEM
CELL TRANSPLANTATION?
SESSION IV
HOW I TREAT RELAPSED
MULTIPLE MYELOMA
DEBATE 3
SHOULD EVERY PATIENT
RECEIVE DARATUMUMAB
IN FIRST LINE?
ROUNDTABLE
MULTIPLE MYELOMA
FROM THE PERSPECTIVE
OF FDA/EMEA AND
FOUNDATIONS
SESSION V
YOU CAN’T BE IMMUNE
FOR IMMUNE THERAPY
ANYMORE
SESSION VI
OTHER PLASMA CELL
DYSCRASIAS
KEYNOTE LECTURES
THE FUTURE OF
MULTIPLE MYELOMA
SELECTED ABSTRACTS
FOR AN ORAL
PRESENTATION
ABSTRACTS SELECTED
AS POSTERS
DISCLOSURES
Connecting haematologists worldwide
through mentorship and lifelong learning
UPCOMING ESH CONFERENCES
ESH plenary conference programmes are designed to place emphasis on leading-edge
basic and clinical research and future perspectives. Ample time is deliberately provided
for in-depth scientific discussion and interaction. Registered participants further benefit
from a variety of opportunities for informal scientific interaction with the world’s leading
experts in their field, including during small Meet the Expert sessions and Mentored
Posters Walks. ESH conference delegates are invited to submit abstracts. Selected
abstracts are presented as brief oral communications or posters.
2021 ESH UPCOMING E-CONFERENCES, LIVE & HYBRID CONFERENCES
2022 1st SEMESTER - ESH UPCOMING LIVE & HYBRID CONFERENCES
info@esh.org - www.esh.org
Follow us on twiter@ESHaematology